Home > Education Hub > We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel

We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel

Drawing on CDMO and biomedical expertise, Alira Health helped AGC Biologics become one of the few companies offering both plasmid production and cell and gene therapy services.

News

Category:

M&A

Published on:

November 29, 2020

We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.

Benvic is a French group leader in the production of highly innovative PVC-based thermoplastic solutions and ecological biopolymers.

For more information, please contact Gabriele Brambilla.

To read the full press release

Click here

Related news

M&A MedTech Pharma

News January 13, 2022

Alira Health Secures an Additional $40M in Funding, Led by Creadev

We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. We intend to use the funds to invest in solutions that actively engage patients(...)

Publications August 3, 2021

What You Should Know Before Choosing a Healthcare Transaction Advisory Firm

What’s most important when selecting a firm for your next transaction? Global experience, staff profiles, technical expertise? To learn more read our latest TAD Infographic.

M&A MedTech Pharma

News April 12, 2021

Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev

Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.

News December 20, 2020

We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS

We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.

Publications November 1, 2020

Five Key Success Factors for Managing Transactions in Full Virtual Mode

It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.

Publications October 10, 2020

Q3 2020 Medical Device Contract Development and Manufacturing M&A Report

Despite the COVID-19 pandemic, M&A activity in the global CDMO industry has been exceptionally strong in 2020 with a record number of transactions completed during the third quarter alone.

News September 11, 2020

We Announce our Role as Advisor to Sagard NewGen

We are pleased to announce our role as Advisor to Sagard NewGen for the equity investment in Laboratoires Delbert. This recent capital raise of €40m supports the company’s growth(...)